Edition:
United States

Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

147.89USD
22 Sep 2017
Change (% chg)

$0.11 (+0.07%)
Prev Close
$147.78
Open
$147.76
Day's High
$148.41
Day's Low
$147.03
Volume
74,517
Avg. Vol
148,686
52-wk High
$163.69
52-wk Low
$95.80

Latest Key Developments (Source: Significant Developments)

Jazz Pharmaceuticals and Immunogen sign deal to develop, commercialize antibody-drug conjugate products
Tuesday, 29 Aug 2017 06:30am EDT 

Aug 29 (Reuters) - Immunogen Inc :Jazz Pharmaceuticals and Immunogen inc announce a strategic collaboration and option agreement to develop and commercialize antibody-drug conjugate products.Immunogen will be responsible for development of three ADC programs prior to any potential opt-in by Jazz.Immunogen Inc - as part of agreement, Jazz will pay Immunogen an upfront payment of $75 million.Immunogen Inc - additionally, Jazz will pay Immunogen up to $100 million in development funding over seven years to support three ADC programs.Immunogen - After any opt-in, Jazz would be responsible for any further development as well as for potential regulatory submissions, commercialization.Immunogen - Programs covered under agreement include IMGN779, a CD33-targeted ADC for treatment of acute myeloid leukemia (AML) in Phase 1 testing.Immunogen - Programs under deal also include IMGN632, a CD123-targeted ADC for hematological malignancies seen to enter clinical testing before end of year.  Full Article

Jazz Pharmac announces offering of $500 mln of exchangeable senior notes
Thursday, 17 Aug 2017 04:07pm EDT 

Aug 17 (Reuters) - Jazz Pharmaceuticals Plc :Jazz Pharmaceuticals announces offering of $500 million of exchangeable senior notes due 2024.Jazz Pharmaceuticals - to use net proceeds to repay all or substantial portion of $500 million of outstanding borrowings under revolving credit facility.  Full Article

Jazz Pharmaceuticals Q2 adjusted earnings per share $2.56
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Jazz Pharmaceuticals Plc :Jazz Pharmaceuticals announces second quarter 2017 financial results.Q2 adjusted earnings per share $2.56.Q2 GAAP earnings per share $1.72.Q2 earnings per share view $2.75 -- Thomson Reuters I/B/E/S.Jazz Pharmaceuticals Plc says affirming its full year 2017 financial guidance.Qtrly total revenues $394.4 million , up 3 percent.FY2017 earnings per share view $11.02, revenue view $1.66 billion -- Thomson Reuters I/B/E/S.Q2 revenue view $410.8 million -- Thomson Reuters I/B/E/S.  Full Article

Jazz Pharmaceuticals announces FDA approval of Vyxeos
Thursday, 3 Aug 2017 10:10am EDT 

Aug 3 (Reuters) - Jazz Pharmaceuticals Plc ::Jazz Pharmaceuticals announces FDA approval of Vyxeos™ (Daunorubicin and Cytarabine) liposome for injection for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).Jazz Pharmaceuticals Plc- ‍Vyxeos will be commercially available within a week​.  Full Article

FDA approves first treatment for certain types of poor-prognosis acute myeloid leukemia
Thursday, 3 Aug 2017 09:39am EDT 

Aug 3 (Reuters) - U.S. Food and Drug Administration::FDA approves first treatment for certain types of poor-prognosis acute myeloid leukemia.U.S. FDA - FDA granted the approval of vyxeos to Jazz Pharmaceuticals‍​.‍FDA-prescribing information for vyxeos includes boxed warning not to interchange vyxeos with other daunorubicin- and/or cytarabine-containing products​.  Full Article

Jazz Pharmaceuticals and XL-protein GmbH enter into license agreement
Wednesday, 26 Jul 2017 04:05pm EDT 

July 26 (Reuters) - Jazz Pharmaceuticals Plc :Jazz Pharmaceuticals and XL-protein GmbH enter into a license agreement on PASylation technology to develop long-acting asparaginase product candidates.Jazz Pharmaceuticals - agreement with XL-protein GmbH for rights to develop, manufacture and commercialize products using XLp's pasylation technology.Jazz Pharmaceuticals Plc - Jazz has paid an upfront payment of $2 million.Jazz Pharmaceuticals Plc - other financial terms are not disclosed.  Full Article

Jazz Pharmaceuticals says on June 28, its unit entered into pharmacy master services agreement with Express Scripts specialty distribution services
Monday, 3 Jul 2017 04:31pm EDT 

July 3 (Reuters) - Jazz Pharmaceuticals Plc ::Jazz Pharmaceuticals says on June 28, its unit entered into a pharmacy master services agreement with express scripts specialty distribution services.Says ‍under master services agreement, jazz is billed monthly for services performed by express scripts.Jazz Pharmaceuticals - pursuant to agreement express scripts provides exclusive distribution and other services to jazz related to sale and marketing of xyrem oral solution in u.s..Jazz Pharmaceuticals plc - master services agreement will expire on June 30, 2019, subject to a one-year extension at option of jazz.  Full Article

Jazz pharmaceuticals announces Q1 2017 financial results
Tuesday, 9 May 2017 04:05pm EDT 

May 9 (Reuters) - Jazz Pharmaceuticals PLC ::Jazz pharmaceuticals announces first quarter 2017 financial results.Q1 adjusted earnings per share $2.31.Q1 GAAP earnings per share $1.41.Q1 revenue $376 million versus I/B/E/S view $377 million.Q1 earnings per share view $2.34 -- Thomson Reuters I/B/E/S.Sees 2017 total net product sales $1,617 million to $1,692 million.Sees 2017 GAAP net income per diluted share $6.55-$7.55.Sees 2017 non-gaap adjusted net income per diluted share $10.70-$11.30.FY2017 earnings per share view $11.12, revenue view $1.67 billion -- Thomson Reuters I/B/E/S.  Full Article

Jazz Pharmaceuticals announces positive results of JZP-110 study
Wednesday, 26 Apr 2017 04:05pm EDT 

April 26 (Reuters) - Jazz Pharmaceuticals Plc :Jazz Pharmaceuticals announces positive results from the phase 3 tones 2 study of jzp-110 in narcolepsy patients with excessive sleepiness.Says expect to submit JZP-110 nda for excessive sleepiness in obstructive sleep apnea and narcolepsy in late 2017.Jazz Pharmaceuticals - most commonly reported AEs in study generally consistent with those observed in phase 2 clinical studies evaluating JZP-110.Says JZP-110 75 mg dose reached statistical significance on co-primary endpoint of mwt.Says JZP-110 75 mg dose did not reach statistical significance on co-primary endpoint of ess.Jazz Pharmaceuticals - there was one patient with two saes on JZP-110 that were considered not treatment related as assessed by investigator.  Full Article

Jazz Pharmaceuticals reports psoitive data from phase 2/3 study of Xyrem
Monday, 24 Apr 2017 04:05pm EDT 

April 24 (Reuters) - Jazz Pharmaceuticals Plc -:Jazz Pharmaceuticals announces positive results from the phase 2/3 express study of xyrem in pediatric patients with narcolepsy with cataplexy.Jazz Pharmaceuticals Plc - xyrem demonstrated statistically significant differences in primary and key secondary efficacy endpoints.Jazz Pharmaceuticals - preliminary safety results consistent with results observed in xyrem studies in adults and xyrem post-marketing experience.  Full Article

BRIEF-Jazz Pharma announces $500 mln offering of 1.50 pct exchangeable senior notes due 2024

* Jazz Pharmaceuticals Plc - ‍offering of $500 million aggregate principal amount of 1.50% exchangeable senior notes due 2024​